Navigation Links
OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
Date:8/4/2009

FT. LAUDERDALE, Fla., Aug. 4 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that the company has acquired the EDC assets of UK based, clinical software provider, Logos Technologies, Ltd. The acquisition will be operated by OmniComm's UK subsidiary, OmniComm Ltd.

Logos' exceptional software is used to collect clinical trial data gathered while conducting Phase I clinical trials. Phase I clinical trials are the first stage of the US or International regulatory approval process, in order to get new drugs and medical devices to the marketplace. The Logos software complements OmniComm's TrialMaster(R) software, which is primarily used in later stage clinical trials. The Logos products cover all aspects of the Phase I process from subject recruitment and clinical workflow management to laboratory sample management. Regular EDC solutions for later stage trials do not include a pro-active data collection system, which is imperative for the very time-controlled data collection during many early stage clinical studies. There are only 3 commonly known Phase I EDC systems in the world that are capable of demonstrating this functionality.

"We look forward to becoming part of OmniComm," said Simon Kemp, Logos Technology Ltd.'s Managing Director. "OmniComm's team of industry professionals was a key factor in our decision making process. We have worked closely with OmniComm in the past with several joint clients and see this as an opportunity to enhance and fully integrate the Logos products with OmniComm's eClinical solutions. Our clients, which include Top 10 Pharmaceutical, leading Academic and Clinical Research Organizations, will also benefit from working with a larger global company like OmniComm. "

"We are pleased to add the Logos products and operations to the OmniComm team," said Cornelis F. Wit, OmniComm's President and CEO. "We believe that the addition of the Logos phase I products is of importance for OmniComm Systems as it will broaden the scope of our integrated eClinical solutions offering. Only a very small number of EDC companies specialize in the Phase I market, therefore this acquisition represents an important addition to our overall corporate growth strategy; Larger pharmaceutical companies in particular will be a prime consumer of this product. This combined with our recent acquisition of eResearch Technology's data capture unit, positions us well to offer our clients with a wide array of state of the art, cost-effective tools to capture and track outcomes of clinical trials."

The Phase I trial sector is among the fastest growing segments of the clinical research industry, according to market research firm, Health Industry Insights. This growth naturally translates to the electronic data capture market, which they forecast will reach $120 million in 2010 for electronic data capture in the phase I sector alone. Solutions for a phase I specific environment must be developed to meet their unique needs and the Logos products are designed specifically for this need.

About Logos Technologies, Ltd.

Logos Technologies, Ltd. is one of the early pioneers in providing world-class solutions to pharmaceutical, contract research organizations and biotechnology companies with electronic data capture (EDC) and clinical management solutions needed to accelerate pharmaceutical research and development.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida and offices in Bonn, Germany, Tula, Russia, California, Connecticut, Georgia, Illinois, New Jersey, New York, North Carolina and Tennessee.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    CONTACT:
    Catherine Lemercier
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    clemercier@omnicomm.com

    Stephen Johnson
    954-377-1726


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies
2. OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology
3. OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific
4. OmniComm Systems Announces 1st Quarter Results of Operations
5. OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC
6. OmniComm Systems, Inc. Experiences Record Year End Results - $18 Million in Signed Contracts for the Year 2008
7. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
8. Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting
9. NYU physicists find way to explore microscopic systems through holographic video
10. Magellan Diagnostic Businesses to Feature Automated Systems and Diagnostic Tests at Clinical Lab Expo
11. Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... to enabling healthier lives through the development of innovative ... of the United States denied ... that the claims of Sequenom,s U.S. Patent No. 6,258,540 ... eligibility criteria established by the Supreme Court,s Mayo Collaborative ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):